Data Show SuperGen's MP-470 is Safe...( DUBLIN Calif. April 15 /- SuperGe...),Health

DUBLIN, Calif., April 15 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that MP-470, its clinical-stage multi-targeted tyrosine kinase inhibitor and Rad51 suppressor, is bioavailable and safe in humans (Abstract No. 4083).

Entitled, "MP-470, a potent oral Rad51 suppressor is safe and tolerable in first-in-human study," the poster highlights data indicating that MP-470 can be safely administered in doses of up to 900 mg per day. Additionally, it was found that Rad51 expression is modulated in a dose-dependent manner. This is consistent with preclinical studies where MP-470 was shown to sensitize cancer cells to DNA damaging agents and radiation therapy through the suppression of Rad51, which is responsible for repair of DNA double strand breaks.

"This is the first Rad51 suppressor that has advanced into Phase 1 clinical trials," said Dr. Gregory Berk, SuperGen's Chief Medical Officer. "These results support the potential use of MP-470 in combination with DNA-damaging chemotherapies as a direct result of its ability to inhibit the repair of double stranded DNA breaks. The lack of toxicity observed to date with MP-470 further supports this clinical development strategy. Later this year, we expect to report preliminary data on a recently initiated, multi-arm Phase 1b clinical trial of MP-470 in combination with standard chemotherapy regimens."

Interim data from the ongoing MP-470 Phase 1 trial was presented. Ten patients with refractory solid tumors participated in this acceler
'/>"/>